This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sentynl Therapeutics, Inc.
Drug Names(s): Rapinyl, sublingual fentanyl, OX 20, EN3267, KW-2246
Description: Rapinyl is a sublingual formulation of fentanyl, an opioid agonist. Rapinyl rapidly disintegrates into ordered units of carriers that adhere to the sublingual mucosa and the active compound dissolves. This allows the drug to rapidly permeate the sublingual mucosa to enter the bloodstream.
Orexo, ProStrakan, and Kyowa Hakko Kirin
In January 2003, Orexo licensed the marketing rights for Rapinyl in Japan to Kyowa Hakko. Upon entering into the licensing agreement, Orexo received a lump sum of $1 mill and has received two milestone payments totaling $ 2.5 mill for the granting of patents and positive reception from the Japanese regulatory authority regarding the clinical testing program for Rapinyl. Under the terms of the agreement, additional milestone payments totaling up to $5.0 million shall be paid out upon conclusion of clinical testing and approval of Rapinyl by the regulatory authority in Japan. Orexo also has, according to the licensing agreement, the right to a single-digit percentage royalty based on sales.
Orexo has a royalty agreement related toproducts and candidate products containing fentanyl for sublingual administration for the treatment of acute pain, chronic pain or breakthrough pain, such as Rapinyl, whereby 10 percent of Orexos revenues...See full deal structure in Biomedtracker
Partners: Kyowa Hakko Kirin Co., Ltd. Gedeon Richter Plc Hisamitsu Pharmaceutical Co., Inc. NewBridge Pharmaceuticals Orexo AB Endo International plc
Additional information available to subscribers only: